Apr 14, 2022 / 12:45PM GMT
Gil Blum - Needham & Company, LLC - Analyst
Good morning, and welcome to day four of the Needham and Company healthcare conference. My name is Gil Blum, and I am a Senior Biotech Analyst here at Needham and Company, covering the immuno-oncology and gene therapy sub-sectors. It is my pleasure to have with me today Dr. Christian Itin, CEO of Autolus. (Operator Instructions)
And with that, Dr. Itin, I think we can get started. Maybe a good place to start, for those who aren't familiar, can you remind us of Autolus's main mission, and maybe its differentiating features in its autologous CAR Ts?
Christian Itin - Autolus Therapeutics plc - CEO
First off, great to be on, and thanks for the invitation, Gil. So at Autolus, we're obviously focusing on CAR T therapies and we're looking at each indication that we're going after, really specifically of what the type of profile is that we need to have to get to transformational outcome. And for our lead program obe-cel, we're focusing on acute lymphoblastic leukemia, and particularly the adult patient population,
Autolus Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers